Terrie Curran - Net Worth and Insider Trading
Terrie Curran Net Worth
The estimated net worth of Terrie Curran is at least $4 Million dollars as of 2024-04-19. Terrie Curran is the President and Chief Executive of Phathom Pharmaceuticals Inc and owns about 414,624 shares of Phathom Pharmaceuticals Inc (PHAT) stock worth over $4 Million. Terrie Curran is the SEE REMARKS of Celgene Corp and owns about 3,081 shares of Celgene Corp (CELG) stock worth over $333,487. Terrie Curran is also the Director of Myovant Sciences Ltd and owns about 0 shares of Myovant Sciences Ltd (MYOV) stock worth over $0. Details can be seen in Terrie Curran's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Terrie Curran has not made any transactions after 2024-03-22 and currently still holds the listed stock(s).
Transaction Summary of Terrie Curran
Terrie Curran Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Terrie Curran owns 3 companies in total, including Myovant Sciences Ltd (MYOV) , Phathom Pharmaceuticals Inc (PHAT) , and Arcutis Biotherapeutics Inc (ARQT) .
Click here to see the complete history of Terrie Curran’s form 4 insider trades.
Insider Ownership Summary of Terrie Curran
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| MYOV | Myovant Sciences Ltd | 2021-09-09 | director |
| PHAT | Phathom Pharmaceuticals Inc | 2024-03-22 | director |
| ARQT | Arcutis Biotherapeutics Inc | 2020-11-02 | director |
Terrie Curran Latest Holdings Summary
Terrie Curran currently owns a total of 3 stocks. Among these stocks, Terrie Curran owns 414,624 shares of Phathom Pharmaceuticals Inc (PHAT) as of March 22, 2024, with a value of $4 Million and a weighting of 92.14%. Terrie Curran owns 3,081 shares of Celgene Corp (CELG) as of September 18, 2019, with a value of $333,487 and a weighting of 7.86%. Terrie Curran also owns 0 shares of Myovant Sciences Ltd (MYOV) as of September 9, 2021, with a value of $0 and a weighting of 0%.
Latest Holdings of Terrie Curran
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| PHAT | Phathom Pharmaceuticals Inc | 2024-03-22 | 414,624 | 9.43 | 3,909,904 |
| CELG | Celgene Corp | 2019-09-18 | 3,081 | 108.24 | 333,487 |
| MYOV | Myovant Sciences Ltd | 2021-09-09 | 0 | 26.98 | 0 |
Holding Weightings of Terrie Curran
Terrie Curran Form 4 Trading Tracker
According to the SEC Form 4 filings, Terrie Curran has made a total of 7 transactions in Phathom Pharmaceuticals Inc (PHAT) over the past 5 years, including 2 buys and 5 sells. The most-recent trade in Phathom Pharmaceuticals Inc is the sale of 16,851 shares on March 22, 2024, which brought Terrie Curran around $153,513.
According to the SEC Form 4 filings, Terrie Curran has made a total of 1 transactions in Celgene Corp (CELG) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in Celgene Corp is the sale of 11,338 shares on September 18, 2019, which brought Terrie Curran around $1 Million.
According to the SEC Form 4 filings, Terrie Curran has made a total of 2 transactions in Myovant Sciences Ltd (MYOV) over the past 5 years, including 0 buys and 2 sells. The most-recent trade in Myovant Sciences Ltd is the sale of 4,850 shares on September 9, 2021, which brought Terrie Curran around $124,063.
Insider Trading History of Terrie Curran
- 1
Terrie Curran Trading Performance
GuruFocus tracks the stock performance after each of Terrie Curran's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Terrie Curran is 56.13%. GuruFocus also compares Terrie Curran's trading performance to market benchmark return within the same time period. The performance of stocks bought by Terrie Curran within 3 months outperforms 2 times out of 2 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Terrie Curran's insider trading performs compared to the benchmark.
Performance of Terrie Curran
Average Return
55.86%
Outperforming Transactions
100%
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 20.44 | 56.13 | 34.26 | 55.86 | ||
| Relative Return to S&P 500(%) | 23.47 | 49.21 | 32.16 | 41.22 |
Terrie Curran Ownership Network
Ownership Network List of Terrie Curran
Ownership Network Relation of Terrie Curran
Terrie Curran Owned Company Details
What does Myovant Sciences Ltd do?
Who are the key executives at Myovant Sciences Ltd?
Terrie Curran is the director of Myovant Sciences Ltd. Other key executives at Myovant Sciences Ltd include 10 percent owner Sumitomo Chemical Co., Ltd. , Chief Commercial Officer Lauren Merendino , and General Counsel & Corp. Secy. Matthew Lang .
Myovant Sciences Ltd (MYOV) Insider Trades Summary
Over the past 18 months, Terrie Curran made no insider transaction in Myovant Sciences Ltd (MYOV). Other recent insider transactions involving Myovant Sciences Ltd (MYOV) include a net sale of 4,051 shares made by Matthew Lang , a net sale of 3,360 shares made by Ferreira Juan Camilo Arjona , and a net purchase of 51,599,200 shares made by Sumitomo Chemical Co., Ltd. .
In summary, during the past 3 months, insiders sold 0 shares of Myovant Sciences Ltd (MYOV) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 19,697 shares of Myovant Sciences Ltd (MYOV) were sold and 51,599,200 shares were bought by its insiders, resulting in a net purchase of 51,579,503 shares.
Myovant Sciences Ltd (MYOV)'s detailed insider trading history can be found in Insider Trading Tracker table.
Myovant Sciences Ltd Insider Transactions
Terrie Curran Mailing Address
Above is the net worth, insider trading, and ownership report for Terrie Curran. You might contact Terrie Curran via mailing address: C/o Myovant Sciences Inc., 320 West 37th Street, 5th Floor, New York Ny 10018.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
